Related Experiment Videos
Evidence-based treatment of patients with ischemic cerebrovascular disease
1Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. rllinas@jhmi.edu
Insights
Clinical trials focusing on specific patient groups with defined lesions, like atrial fibrillation or carotid artery stenosis, are most helpful. Grouping all brain ischemia patients together is less useful for guiding treatment decisions.
Area of Science:
- Neurology
- Cardiology
- Vascular Surgery
Background:
- Trials grouping all brain ischemia patients are less clinically useful.
- Modern technology enables precise characterization of cerebrovascular and cardiac conditions.
- Understanding specific causative lesions is crucial for effective patient care.
Purpose of the Study:
- To highlight the importance of patient stratification in clinical trials for brain ischemia.
- To emphasize the need for trials focusing on specific etiological factors.
- To guide clinicians in applying trial data to individual patients.
Main Methods:
- Review of current clinical trial methodologies in cerebrovascular disease.
- Discussion of advancements in diagnostic technology for lesion identification.
- Analysis of the impact of patient heterogeneity on trial outcomes.
Main Results:
- Trials with defined patient cohorts (e.g., atrial fibrillation, carotid stenosis) yield more applicable results.
- Comprehensive diagnostic capabilities allow for detailed etiological assessment.
- Treatment should target the underlying cause rather than solely the extent of brain damage.
Conclusions:
- Future trials should focus on rigorously defined patient populations using advanced diagnostics.
- Clinicians must critically evaluate trial applicability based on individual patient profiles.
- Personalized medicine in cerebrovascular disease requires precise etiological diagnosis.
Abstract:
The results of trials that study patients with defined lesions (atrial fibrillation without valvular heart disease, various severities of carotid artery stenosis in the neck, intracranial artery stenosis) are very helpful for clinicians caring for patients with those conditions. On the other hand, trials that group all patients with brain ischemia together are not very helpful. Modern technology now makes it possible to define quickly and safely: (1) the location, nature, and severity of causative cerebrovascular, cardiac, and aortic lesions; (2) blood constituents and coagulability; and, (3) the presence, location, and severity of ischemic brain damage. As in all medicine, treatment should be aimed at the cause of disease, not the time course and severity of present damage. Clearly, more trials are needed in patients who have been studied thoroughly using modern technology. Until then, clinicians must understand the context of the trial data to determine if the results are applicable to Mr. or Ms. Jones, and the patients sitting before them in the office or in the hospital bed.